investors should consider putting their money in this undervalued chinabased biopharmaceutical stock poised to rally more than 40 jpmorgan chase says analyst xiling chen initiated coverage of beigene with an overweight rating saying in a note to clients monday that the companys products should drive strong growth ahead we see beigene shares as undervalued given quality of assetsgrowth and highlight the stock as among our top picks in the sector he wrote chen placed a 296 price target on the stock which suggests that shares could rally another 46 from mondays close the shares are listed in the us as an adr in particular chen believes that the companys three internallydeveloped drugs are wellpositioned to continue to gain share in their respective markets and that beigene offers one of the most diverse portfolios compared to its chinese biopharma peers at the same time the company is among one of the only chinese developers with products approved in the us giving it another leg up over some of its competitors we see beigene offering bestinclass clinical development and partnership skills chen wrote beigene has built robust clinical development and business development capabilities unmatched by most chinese competitors in our view shares of beigene have fallen more than 25 this year cnbcs michael bloom contributed reporting